Therefore, in the CXCR2 Inhibition – a novel approach to treating CoronAry heart DiseAse (CICADA) study, we aim to perform a randomised, placebo-controlled, double-blind trial to investigate the effect of the CXCR2 inhibitor AZD5069 on CFR and coronary plaque morphology. Here, CXCR2 is linked to coronary artery disorder.